universal cd7-specific chimeric antigen receptor gene-engineered t cells

Universal CD7-specific chimeric antigen receptor (CAR) gene-engineered T cells are a form of allogeneic CAR-T cell therapy designed to target the CD7 antigen, which is highly expressed on malignant T lymphocytes in diseases such as T-cell acute lymphoblastic leukemia (T-ALL), T-cell lymphoblastic lymphoma (T-LBL), and some cases of acute myeloid leukemia (AML). These therapies use advanced gene-editing techniques—such as CRISPR/Cas9 or base editing—to disrupt endogenous CD7 expression in donor-derived T cells. This prevents fratricide (self-killing among CAR-Ts due to shared target expression) and allows for the production of "universal" off-the-shelf products that can be administered to multiple patients. The engineered CAR typically consists of an anti-CD7 single-chain variable fragment fused with intracellular signaling domains like 4-1BB and CD3ζ. Universal CD7 CAR-T cell therapies have shown high rates of complete remission in relapsed/refractory hematologic malignancies expressing CD7, with ongoing clinical trials evaluating their safety and efficacy[1][3][4].

Other names

universal cd7 car t cellsgene-edited universal cd7 car t cellsanti-cd7 car-t cellsanti-cd-7 car-t cellsanti-cd 7 car-t cells